CTLT(Delisted)
Catalent·NYSE
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
Low Cash Short-term Debt Ratio
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CTLT
Catalent, Inc.
A global provider of development and manufacturing solutions for pharmaceutical, biotechnology, and consumer health companies
14 Schoolhouse Road, Somerset, New Jersey 08873
--
Catalent, Inc., is a leading global provider of advanced drug delivery technology and development and manufacturing solutions; protein, cell and gene therapy biological products and consumer health products. The company's oral, injection, cell and gene therapy and cell and respiratory delivery technologies address the full diversity of the pharmaceutical industry, including small molecules; protein, cell and gene therapy biological products; and consumer health products.
Company Financials
EPS
CTLT has released its 2025 Q1 earnings. EPS was reported at -0.13, versus the expected 0.05, missing expectations. The chart below visualizes how CTLT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CTLT has released its 2025 Q1 earnings report, with revenue of 1.02B, reflecting a YoY change of 4.18%, and net profit of -129.00M, showing a YoY change of 83.00%. The Sankey diagram below clearly presents CTLT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
